title: Is structural damage evaluation by traditional radiographs still relevant in rheumatoid arthritis clinical trials?
authors.affiliation: Associate Professor, Department of Medicine, Université de Montréal, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec; bharaoui@videotron.ca.
authors.forename: Boulos
authors.initials: B
authors.lastname: Haraoui
authors.affiliation: Professor of Medicine, Division of Rheumatology, University of Ottawa, Department of Medicine, Ottawa Hospital, Ottawa;
authors.forename: Jacob
authors.initials: J
authors.lastname: Karsh
authors.affiliation: Professor, Department of Medicine, Western University, Rheumatology Division, St. Joseph's Health Care, London;
authors.forename: Janet E
authors.initials: JE
authors.lastname: Pope
authors.affiliation: Head, Division of Rheumatology, Southlake Regional Health Centre, Newmarket;
authors.forename: J Carter
authors.initials: JC
authors.lastname: Thorne
authors.affiliation: Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada.
authors.forename: Edward C
authors.initials: EC
authors.lastname: Keystone
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000503:physiopathology; D001175:Arthrography / Q000379:methods*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents